{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:19:56Z","timestamp":1772209196411,"version":"3.50.1"},"reference-count":18,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Advances in treatment deintensification for human papillomavirus\u2010associated oropharyngeal cancer include use of transoral surgery to permit reduction in pathologic risk\u2010based postoperative therapy after transoral resection. The E3311 cooperative group trial demonstrated 3\u2010year progression\u2010free survival (PFS) of 95% for intermediate risk patients treated with 50\u00a0Gy radiation alone, with no decrement for those with a smoking history. Favorable risk patients could be observed, with a 3\u2010year PFS of 93%. Reduction in radiation dose is also feasible for favorable risk patients (low or no smoking history and low stage) treated with chemoradiation on the NRG HN002 trial, where 2\u2010year PFS was 90.7%. For those favorable risk patients treated with radiation alone, 2\u2010year PFS was 87.7% and this arm did not meet criteria for further testing. Important phase 3 trials of immunotherapy in first\u2010line treatment of recurrent and\/or metastatic head and neck cancer were also reported in 2022. For patients with nonnasopharyngeal sites of disease, the combination of the programmed death\u20101\u2013directed antibody nivolumab plus the anti\u2013CTLA\u20104 agent ipilimumab was not superior to chemotherapy plus cetuximab in the Checkmate 651 trial. However, in an important breakthrough for patients with nasopharyngeal cancer, the JUPITER\u201002 trial, conducted in China, Singapore, and Taiwan among patients with predominantly Epstein\u2010Barr virus\u2010related cancers, demonstrated a significant improvement in PFS (hazard ratio, 0.52) when toripalimab was added to gemcitabine\/cisplatin chemotherapy. Immature survival data indicate overall survival will likely also be impacted.<\/jats:p>","DOI":"10.1002\/cncr.34654","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T09:43:55Z","timestamp":1674553435000},"page":"1308-1312","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Top advances of the year: Head and neck cancer"],"prefix":"10.1002","volume":"129","author":[{"given":"Avanti","family":"Verma","sequence":"first","affiliation":[{"name":"Department of Surgery Yale School of Medicine  New Haven Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4660-1859","authenticated-orcid":false,"given":"Barbara","family":"Burtness","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Yale School of Medicine  New Haven Connecticut USA"},{"name":"Yale Cancer Center Yale School of Medicine  New Haven Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0912217"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn011"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.otc.2020.07.006"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.08.033"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01752"},{"key":"e_1_2_6_7_1","first-page":"870","article-title":"The development and validation of a dysphagia\u2010specific quality\u2010of\u2010life questionnaire for patients with head and neck cancer: the MD Anderson dysphagia inventory","volume":"127","author":"Chen AY","year":"2001","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104797"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03128"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_238315"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1602252"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.001"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.6511"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02198"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.2113"},{"key":"e_1_2_6_18_1","unstructured":"US National Library of Medicine.Study of nivolumab in combination with ipilimumab versus nivolumab in combination with ipilimumab placebo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 714). Accessed September 17 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02823574?term=checkmate+714%26draw=2%26rank=1"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010021\u201001444\u20100"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34654","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.34654","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:32:27Z","timestamp":1760265147000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.34654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1002\/cncr.34654"],"URL":"https:\/\/doi.org\/10.1002\/cncr.34654","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]},"assertion":[{"value":"2023-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}